An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)

BACKGROUND: Shortening duration of peginterferon-based HCV treatment reduces associated burden for patients. Primary objectives of this study were to assess the efficacy against the minimally acceptable response rate 12 weeks post-treatment (SVR12) and safety of simeprevir plus PR in treatment-naïve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Asselah, Tarik, Moreno, Christophe, Sarrazin, Christoph, Gschwantler, Michael, Foster, Graham R., Craxí, Antonio, Buggisch, Peter, Ryan, Robert, Lenz, Oliver, Scott, Jane, Van Dooren, Gino, Lonjon-Domanec, Isabelle, Schlag, Michael, Buti, Maria
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4948848/
https://ncbi.nlm.nih.gov/pubmed/27428331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0158526
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados